Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to -$1.3 million.

  • Iradimed's Cash from Investing Activities rose 6850.16% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.1 million, marking a year-over-year decrease of 7302.58%. This contributed to the annual value of -$8.8 million for FY2024, which is 1011.12% down from last year.
  • Iradimed's Cash from Investing Activities amounted to -$1.3 million in Q3 2025, which was up 6850.16% from -$2.8 million recorded in Q2 2025.
  • In the past 5 years, Iradimed's Cash from Investing Activities ranged from a high of $782980.0 in Q2 2021 and a low of -$6.6 million during Q1 2023
  • Moreover, its 5-year median value for Cash from Investing Activities was -$478803.0 (2024), whereas its average is -$1.3 million.
  • In the last 5 years, Iradimed's Cash from Investing Activities surged by 17254.66% in 2021 and then tumbled by 144393.85% in 2023.
  • Iradimed's Cash from Investing Activities (Quarter) stood at $259778.0 in 2021, then crashed by 281.57% to -$471676.0 in 2022, then tumbled by 34.16% to -$632816.0 in 2023, then crashed by 383.04% to -$3.1 million in 2024, then skyrocketed by 58.66% to -$1.3 million in 2025.
  • Its Cash from Investing Activities stands at -$1.3 million for Q3 2025, versus -$2.8 million for Q2 2025 and -$3.9 million for Q1 2025.